• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB 1.40% $1.09

MESOBLAST LIMITED - Announcements

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

Announcements


MSB Response to ASX Aware Letter QueryPRICE SENSITIVE17/11/17 download Created with Sketch. 508.34KB
MSB Results of Meeting16/11/17 download Created with Sketch. 172.37KB
MSB CEO Presentation to 2017 Annual General Meeting16/11/17 download Created with Sketch. 3.72MB
MSB Chairman's Address to Shareholders16/11/17 download Created with Sketch. 93.39KB
MSB Ceasing to be a substantial holder15/11/17 download Created with Sketch. 2.58MB
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/17 download Created with Sketch. 201.68KB
MSB First Quarter Results Presentation15/11/17 download Created with Sketch. 3.73MB
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/17 download Created with Sketch. 366.77KB
MSB Becoming a substantial holder13/11/17 download Created with Sketch. 6.28MB
MSB RA Phase 2 Trial Results Presented At ACR Annual MeetingPRICE SENSITIVE13/11/17 download Created with Sketch. 127.42KB
MSB Mesoblast Presents At Credit Suisse Healthcare Conference09/11/17 download Created with Sketch. 71.96KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/17 download Created with Sketch. 113.37KB
MSB Ceasing to be a substantial holder30/10/17 download Created with Sketch. 1.06MB
MSB Ceasing to be a substantial holder27/10/17 download Created with Sketch. 117.71KB
MSB Becoming a substantial holder27/10/17 download Created with Sketch. 3.99MB
MSB Annual Report to shareholders16/10/17 download Created with Sketch. 2.81MB
MSB Notice of Annual General Meeting/Proxy Form16/10/17 download Created with Sketch. 299.88KB
MSB Appendix 4G and Corporate Governance Statement16/10/17 download Created with Sketch. 184.8KB
MSB Appendix 3B06/10/17 download Created with Sketch. 78.38KB
MSB End-Stage Heart Failure Trial Completes EnrollmentPRICE SENSITIVE28/09/17 download Created with Sketch. 116.85KB
MSB Mesoblast Corporate Updates at Healthcare ConferencesPRICE SENSITIVE25/09/17 download Created with Sketch. 90.75KB
MSB Change of Director's Interest Notices25/09/17 download Created with Sketch. 232.91KB
MSB Appendix 3B18/09/17 download Created with Sketch. 137.7KB
MSB Mesoblast Completes A$50.7 Million Raise15/09/17 download Created with Sketch. 86.49KB
MSB Change of Director Interest and Substantial Holding Notices06/09/17 download Created with Sketch. 321.52KB
MSB Change in substantial holding06/09/17 download Created with Sketch. 80.17KB
MSB Retail Entitlement OfferPRICE SENSITIVE01/09/17 download Created with Sketch. 682.6KB
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/17 download Created with Sketch. 262.07KB
MSB Annual Financial Results Presentation30/08/17 download Created with Sketch. 3.27MB
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/17 download Created with Sketch. 1.33MB
MSB Underwritten A$50.7M Raise Closes Institutional AllocationPRICE SENSITIVE29/08/17 download Created with Sketch. 89.69KB
MSB Cleansing notice25/08/17 download Created with Sketch. 142.32KB
MSB Appendix 3B25/08/17 download Created with Sketch. 138.37KB
MSB Fully Underwritten Entitlement Offer Presentation25/08/17 download Created with Sketch. 3.69MB
MSB Fully Underwritten A$50.7 Million Entitlement OfferPRICE SENSITIVE25/08/17 download Created with Sketch. 171.9KB
MSB Trading HaltPRICE SENSITIVE25/08/17 download Created with Sketch. 333.06KB
MSB Potential For Accelerated Market Entry In Advanced CHFPRICE SENSITIVE23/08/17 download Created with Sketch. 92.24KB
MSB Positive Results of MSB Therapy in Osteoarthritis PublishedPRICE SENSITIVE16/08/17 download Created with Sketch. 111.07KB
MSB Release of shares from voluntary escrow08/08/17 download Created with Sketch. 83.69KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/17 download Created with Sketch. 96.32KB
MSB Change in substantial holding13/07/17 download Created with Sketch. 278.85KB
MSB Cleansing notice and Appendix 3B10/07/17 download Created with Sketch. 233.9KB
MSB Mesoblast RA Results Presented At EULAR CongressPRICE SENSITIVE22/06/17 download Created with Sketch. 73.88KB
MSB MSB Provides Q3 Operational Highlights and Financial ResultsPRICE SENSITIVE25/05/17 download Created with Sketch. 240.41KB
MSB Third Quarter Results Presentation25/05/17 download Created with Sketch. 2.93MB
MSB Third Quarter Financial Results On Form 6-KPRICE SENSITIVE25/05/17 download Created with Sketch. 3.9MB
MSB Change of Director's Interest Notice02/05/17 download Created with Sketch. 90.45KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE28/04/17 download Created with Sketch. 97.45KB
MSB Change in substantial holding24/04/17 download Created with Sketch. 394.72KB
MSB Successful Interim Analysis in Phase 3 Heart Failure TrialPRICE SENSITIVE10/04/17 download Created with Sketch. 369.91KB
MSB Mesoblast Receives A$3.7m From Aus Govt For R&DPRICE SENSITIVE06/04/17 download Created with Sketch. 65.87KB
MSB FDA Clears Heart Disease Trial At Boston Childrens HospitalPRICE SENSITIVE04/04/17 download Created with Sketch. 93.12KB
MSB Change in substantial holding03/04/17 download Created with Sketch. 317.03KB
MSB Becoming a substantial holder from TEK31/03/17 download Created with Sketch. 110.17KB
MSB Cleansing notice and Appendix 3B31/03/17 download Created with Sketch. 234.09KB
MSB Process Initiated For CHF P3 Interim AnalysisPRICE SENSITIVE31/03/17 download Created with Sketch. 92.03KB
MSB Mesoblast Raises US$40 MillionPRICE SENSITIVE27/03/17 download Created with Sketch. 90.92KB
MSB Durable Three Year Outcomes in Disc DiseasePRICE SENSITIVE15/03/17 download Created with Sketch. 104.05KB
MSB FDA Grants Mesoblast Fast Track Designation For GVHDPRICE SENSITIVE07/03/17 download Created with Sketch. 92.34KB
MSB Mesoblast Provides Half Year Results And Corporate Update27/02/17 download Created with Sketch. 219.84KB
MSB Half Year Results Presentation27/02/17 download Created with Sketch. 2.68MB
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE27/02/17 download Created with Sketch. 3.87MB
MSB Presentation On Mesoblast RA P2 9 Month Trial Results16/02/17 download Created with Sketch. 2.5MB
MSB Positive Nine Month RA Results For Mesoblast Cell TherapyPRICE SENSITIVE16/02/17 download Created with Sketch. 161.63KB
MSB Published Results Show MSB Cells Effective In RA ModelPRICE SENSITIVE13/02/17 download Created with Sketch. 115.34KB
MSB Release of shares from voluntary escrow10/02/17 download Created with Sketch. 83.69KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/17 download Created with Sketch. 60.43KB
MSB Mesoblast Director Recognized For Cardiovascular LeadershipPRICE SENSITIVE31/01/17 download Created with Sketch. 91.54KB
MSB MSB Presentation To Annual J.P.Morgan Healthcare Conference13/01/17 download Created with Sketch. 3.7MB
MSB Presentation at JP Morgan Healthcare Conference11/01/17 download Created with Sketch. 285.21KB
MSB MSB Receives A$29.6Million, Appendix 3B Share Issue09/01/17 download Created with Sketch. 237.85KB
MSB Mesoblast And Mallinckrodt Enter Into AgreementPRICE SENSITIVE23/12/16 download Created with Sketch. 95.59KB
MSB New US Accelerated Approval Pathway For Cell Therapies09/12/16 download Created with Sketch. 91.21KB
MSB S&P DJ Indices Announces December Quarterly Rebalance09/12/16 download Created with Sketch. 111.26KB
MSB MD Anderson and NIH Fund Trial Using Mesoblast TechnologiesPRICE SENSITIVE06/12/16 download Created with Sketch. 94.77KB
MSB Results of Meeting22/11/16 download Created with Sketch. 198.05KB
MSB CEO Presentation to 2016 Annual General Meeting22/11/16 download Created with Sketch. 932.09KB
MSB Chairman's Address to Shareholders22/11/16 download Created with Sketch. 267.86KB
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/16 download Created with Sketch. 204.69KB
MSB First Quarter Results Presentation15/11/16 download Created with Sketch. 552.26KB
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/16 download Created with Sketch. 2.03MB
MSB Successful Interim Futility Analysis In P3 Trial for GVHDPRICE SENSITIVE14/11/16 download Created with Sketch. 104.7KB
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE31/10/16 download Created with Sketch. 57.51KB
MSB Annual Report to shareholders-MSB.AX 21/10/16 download Created with Sketch. 5.98MB
MSB Notice of Annual General Meeting/Proxy Form-MSB.AX 21/10/16 download Created with Sketch. 289.87KB
MSB Appendix 4G And Corporate Governance Statement-MSB.AX 21/10/16 download Created with Sketch. 170.94KB
MSB Mesoblast Receives Frost & Sullivan 2016 Cell Therapy Award-MSB.AX 18/10/16 download Created with Sketch. 105.77KB
MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX PRICE SENSITIVE12/10/16 download Created with Sketch. 90.23KB
MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX PRICE SENSITIVE06/10/16 download Created with Sketch. 116.34KB
MSB Mesoblast Appoints Bill Burns As Vice Chairman-MSB.AX 01/09/16 download Created with Sketch. 86.13KB
MSB Annual Financial Results Presentation-MSB.AX 28/08/16 download Created with Sketch. 659.55KB
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX PRICE SENSITIVE28/08/16 download Created with Sketch. 5.63MB
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX PRICE SENSITIVE28/08/16 download Created with Sketch. 210.61KB
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX PRICE SENSITIVE25/08/16 download Created with Sketch. 210.61KB
MSB Annual Financial Results Presentation-MSB.AX 25/08/16 download Created with Sketch. 659.55KB
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX PRICE SENSITIVE25/08/16 download Created with Sketch. 5.63MB
MSB Appendix 3B-MSB.AX 19/08/16 download Created with Sketch. 179.37KB
MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX PRICE SENSITIVE17/08/16 download Created with Sketch. 128.67KB
MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX PRICE SENSITIVE09/08/16 download Created with Sketch. 138.83KB
MSB Presentation On Mesoblast RA P2 Trial Results-MSB.AX 09/08/16 download Created with Sketch. 1.88MB
MSB Response to ASX Aware Letter Query
17/11/17PRICE SENSITIVE download Created with Sketch. 508.34KB
MSB Results of Meeting
16/11/17 download Created with Sketch. 172.37KB
MSB CEO Presentation to 2017 Annual General Meeting
16/11/17 download Created with Sketch. 3.72MB
MSB Chairman's Address to Shareholders
16/11/17 download Created with Sketch. 93.39KB
MSB Ceasing to be a substantial holder
15/11/17 download Created with Sketch. 2.58MB
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/17PRICE SENSITIVE download Created with Sketch. 201.68KB
MSB First Quarter Results Presentation
15/11/17 download Created with Sketch. 3.73MB
MSB First Quarter Results On Form 6K
15/11/17PRICE SENSITIVE download Created with Sketch. 366.77KB
MSB Becoming a substantial holder
13/11/17 download Created with Sketch. 6.28MB
MSB RA Phase 2 Trial Results Presented At ACR Annual Meeting
13/11/17PRICE SENSITIVE download Created with Sketch. 127.42KB
MSB Mesoblast Presents At Credit Suisse Healthcare Conference
09/11/17 download Created with Sketch. 71.96KB
MSB Appendix 4C - quarterly
31/10/17PRICE SENSITIVE download Created with Sketch. 113.37KB
MSB Ceasing to be a substantial holder
30/10/17 download Created with Sketch. 1.06MB
MSB Ceasing to be a substantial holder
27/10/17 download Created with Sketch. 117.71KB
MSB Becoming a substantial holder
27/10/17 download Created with Sketch. 3.99MB
MSB Annual Report to shareholders
16/10/17 download Created with Sketch. 2.81MB
MSB Notice of Annual General Meeting/Proxy Form
16/10/17 download Created with Sketch. 299.88KB
MSB Appendix 4G and Corporate Governance Statement
16/10/17 download Created with Sketch. 184.8KB
MSB Appendix 3B
06/10/17 download Created with Sketch. 78.38KB
MSB End-Stage Heart Failure Trial Completes Enrollment
28/09/17PRICE SENSITIVE download Created with Sketch. 116.85KB
MSB Mesoblast Corporate Updates at Healthcare Conferences
25/09/17PRICE SENSITIVE download Created with Sketch. 90.75KB
MSB Change of Director's Interest Notices
25/09/17 download Created with Sketch. 232.91KB
MSB Appendix 3B
18/09/17 download Created with Sketch. 137.7KB
MSB Mesoblast Completes A$50.7 Million Raise
15/09/17 download Created with Sketch. 86.49KB
MSB Change of Director Interest and Substantial Holding Notices
06/09/17 download Created with Sketch. 321.52KB
MSB Change in substantial holding
06/09/17 download Created with Sketch. 80.17KB
MSB Retail Entitlement Offer
01/09/17PRICE SENSITIVE download Created with Sketch. 682.6KB
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/17PRICE SENSITIVE download Created with Sketch. 262.07KB
MSB Annual Financial Results Presentation
30/08/17 download Created with Sketch. 3.27MB
MSB Preliminary Final Report including Appendix 4E
30/08/17PRICE SENSITIVE download Created with Sketch. 1.33MB
MSB Underwritten A$50.7M Raise Closes Institutional Allocation
29/08/17PRICE SENSITIVE download Created with Sketch. 89.69KB
MSB Cleansing notice
25/08/17 download Created with Sketch. 142.32KB
MSB Appendix 3B
25/08/17 download Created with Sketch. 138.37KB
MSB Fully Underwritten Entitlement Offer Presentation
25/08/17 download Created with Sketch. 3.69MB
MSB Fully Underwritten A$50.7 Million Entitlement Offer
25/08/17PRICE SENSITIVE download Created with Sketch. 171.9KB
MSB Trading Halt
25/08/17PRICE SENSITIVE download Created with Sketch. 333.06KB
MSB Potential For Accelerated Market Entry In Advanced CHF
23/08/17PRICE SENSITIVE download Created with Sketch. 92.24KB
MSB Positive Results of MSB Therapy in Osteoarthritis Published
16/08/17PRICE SENSITIVE download Created with Sketch. 111.07KB
MSB Release of shares from voluntary escrow
08/08/17 download Created with Sketch. 83.69KB
MSB Appendix 4C - quarterly
31/07/17PRICE SENSITIVE download Created with Sketch. 96.32KB
MSB Change in substantial holding
13/07/17 download Created with Sketch. 278.85KB
MSB Cleansing notice and Appendix 3B
10/07/17 download Created with Sketch. 233.9KB
MSB Mesoblast RA Results Presented At EULAR Congress
22/06/17PRICE SENSITIVE download Created with Sketch. 73.88KB
MSB MSB Provides Q3 Operational Highlights and Financial Results
25/05/17PRICE SENSITIVE download Created with Sketch. 240.41KB
MSB Third Quarter Results Presentation
25/05/17 download Created with Sketch. 2.93MB
MSB Third Quarter Financial Results On Form 6-K
25/05/17PRICE SENSITIVE download Created with Sketch. 3.9MB
MSB Change of Director's Interest Notice
02/05/17 download Created with Sketch. 90.45KB
MSB Appendix 4C - quarterly
28/04/17PRICE SENSITIVE download Created with Sketch. 97.45KB
MSB Change in substantial holding
24/04/17 download Created with Sketch. 394.72KB
MSB Successful Interim Analysis in Phase 3 Heart Failure Trial
10/04/17PRICE SENSITIVE download Created with Sketch. 369.91KB
MSB Mesoblast Receives A$3.7m From Aus Govt For R&D
06/04/17PRICE SENSITIVE download Created with Sketch. 65.87KB
MSB FDA Clears Heart Disease Trial At Boston Childrens Hospital
04/04/17PRICE SENSITIVE download Created with Sketch. 93.12KB
MSB Change in substantial holding
03/04/17 download Created with Sketch. 317.03KB
MSB Becoming a substantial holder from TEK
31/03/17 download Created with Sketch. 110.17KB
MSB Cleansing notice and Appendix 3B
31/03/17 download Created with Sketch. 234.09KB
MSB Process Initiated For CHF P3 Interim Analysis
31/03/17PRICE SENSITIVE download Created with Sketch. 92.03KB
MSB Mesoblast Raises US$40 Million
27/03/17PRICE SENSITIVE download Created with Sketch. 90.92KB
MSB Durable Three Year Outcomes in Disc Disease
15/03/17PRICE SENSITIVE download Created with Sketch. 104.05KB
MSB FDA Grants Mesoblast Fast Track Designation For GVHD
07/03/17PRICE SENSITIVE download Created with Sketch. 92.34KB
MSB Mesoblast Provides Half Year Results And Corporate Update
27/02/17 download Created with Sketch. 219.84KB
MSB Half Year Results Presentation
27/02/17 download Created with Sketch. 2.68MB
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/17PRICE SENSITIVE download Created with Sketch. 3.87MB
MSB Presentation On Mesoblast RA P2 9 Month Trial Results
16/02/17 download Created with Sketch. 2.5MB
MSB Positive Nine Month RA Results For Mesoblast Cell Therapy
16/02/17PRICE SENSITIVE download Created with Sketch. 161.63KB
MSB Published Results Show MSB Cells Effective In RA Model
13/02/17PRICE SENSITIVE download Created with Sketch. 115.34KB
MSB Release of shares from voluntary escrow
10/02/17 download Created with Sketch. 83.69KB
MSB Appendix 4C - quarterly
31/01/17PRICE SENSITIVE download Created with Sketch. 60.43KB
MSB Mesoblast Director Recognized For Cardiovascular Leadership
31/01/17PRICE SENSITIVE download Created with Sketch. 91.54KB
MSB MSB Presentation To Annual J.P.Morgan Healthcare Conference
13/01/17 download Created with Sketch. 3.7MB
MSB Presentation at JP Morgan Healthcare Conference
11/01/17 download Created with Sketch. 285.21KB
MSB MSB Receives A$29.6Million, Appendix 3B Share Issue
09/01/17 download Created with Sketch. 237.85KB
MSB Mesoblast And Mallinckrodt Enter Into Agreement
23/12/16PRICE SENSITIVE download Created with Sketch. 95.59KB
MSB New US Accelerated Approval Pathway For Cell Therapies
09/12/16 download Created with Sketch. 91.21KB
MSB S&P DJ Indices Announces December Quarterly Rebalance
09/12/16 download Created with Sketch. 111.26KB
MSB MD Anderson and NIH Fund Trial Using Mesoblast Technologies
06/12/16PRICE SENSITIVE download Created with Sketch. 94.77KB
MSB Results of Meeting
22/11/16 download Created with Sketch. 198.05KB
MSB CEO Presentation to 2016 Annual General Meeting
22/11/16 download Created with Sketch. 932.09KB
MSB Chairman's Address to Shareholders
22/11/16 download Created with Sketch. 267.86KB
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/16PRICE SENSITIVE download Created with Sketch. 204.69KB
MSB First Quarter Results Presentation
15/11/16 download Created with Sketch. 552.26KB
MSB First Quarter Results On Form 6K
15/11/16PRICE SENSITIVE download Created with Sketch. 2.03MB
MSB Successful Interim Futility Analysis In P3 Trial for GVHD
14/11/16PRICE SENSITIVE download Created with Sketch. 104.7KB
MSB Appendix 4C - quarterly-MSB.AX
31/10/16PRICE SENSITIVE download Created with Sketch. 57.51KB
MSB Annual Report to shareholders-MSB.AX
21/10/16 download Created with Sketch. 5.98MB
MSB Notice of Annual General Meeting/Proxy Form-MSB.AX
21/10/16 download Created with Sketch. 289.87KB
MSB Appendix 4G And Corporate Governance Statement-MSB.AX
21/10/16 download Created with Sketch. 170.94KB
MSB Mesoblast Receives Frost & Sullivan 2016 Cell Therapy Award-MSB.AX
18/10/16 download Created with Sketch. 105.77KB
MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX
12/10/16PRICE SENSITIVE download Created with Sketch. 90.23KB
MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX
06/10/16PRICE SENSITIVE download Created with Sketch. 116.34KB
MSB Mesoblast Appoints Bill Burns As Vice Chairman-MSB.AX
01/09/16 download Created with Sketch. 86.13KB
MSB Annual Financial Results Presentation-MSB.AX
28/08/16 download Created with Sketch. 659.55KB
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX
28/08/16PRICE SENSITIVE download Created with Sketch. 5.63MB
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX
28/08/16PRICE SENSITIVE download Created with Sketch. 210.61KB
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX
25/08/16PRICE SENSITIVE download Created with Sketch. 210.61KB
MSB Annual Financial Results Presentation-MSB.AX
25/08/16 download Created with Sketch. 659.55KB
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX
25/08/16PRICE SENSITIVE download Created with Sketch. 5.63MB
MSB Appendix 3B-MSB.AX
19/08/16 download Created with Sketch. 179.37KB
MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX
17/08/16PRICE SENSITIVE download Created with Sketch. 128.67KB
MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX
09/08/16PRICE SENSITIVE download Created with Sketch. 138.83KB
MSB Presentation On Mesoblast RA P2 Trial Results-MSB.AX
09/08/16 download Created with Sketch. 1.88MB
(20min delay)
Last
$1.09
Change
0.015(1.40%)
Mkt cap ! $1.238B
Open High Low Value Volume
$1.11 $1.12 $1.08 $11.51M 10.52M

Buyers (Bids)

No. Vol. Price($)
2 17804 $1.09
 

Sellers (Offers)

Price($) Vol. No.
$1.09 230637 5
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
$1.09
  Change
0.015 ( 1.85 %)
Open High Low Volume
$1.10 $1.12 $1.08 1937390
Last updated 15.59pm 03/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.